Skip to main content
. 2022 May 19;8(7):1010–1018. doi: 10.1001/jamaoncol.2022.1059

Figure 1. GeparX Study Design.

Figure 1.

AUC indicates area under the curve; BC, breast cancer; Dmab, denosumab; EC, epirubicin and cyclophosphamide; nP, nab-paclitaxel; pCR, pathological complete response; SC, subcutaneously; sTILs, stromal tumor-infiltrating lymphocytes; TNBC, triple-negative BC; wk, weekly.